Dual effect of vitamin D
Breast cancer
Calcitriol
Fibroblasts
Tumor microenvironment
Vitamin D3
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
15 Feb 2024
15 Feb 2024
Historique:
received:
24
10
2023
accepted:
05
02
2024
medline:
16
2
2024
pubmed:
16
2
2024
entrez:
15
2
2024
Statut:
epublish
Résumé
Cancer-associated fibroblasts (CAFs) play an important role in the tumor microenvironment. Despite the well-known in vitro antitumoral effect of vitamin D CAFs were cultured with 1 and 10 nM calcitriol and their phenotype; gene expression, protein expression, and secretion were assessed. Calcitriol-treated CAFs-conditioned media (CM) were used to analyze the effect of CAFs on the migration and protein expression of MCF-7 and MDA-MB-231 cells. Tumor tissues from VD The effects of calcitriol on breast CAFs, both at the gene and protein levels, are complex, reflecting the immunosuppressive or procancer properties of CAFs. The anticancer polarization of CAFs following ex vivo calcitriol treatment may result from decreased CCL2, TNC (gene and protein), MMP9, and MMP-2, while the opposite effect may result from increased PDPN, TIMP1 (gene and protein), and SPP1. Despite these multifaceted effects of calcitriol on molecule expression, CAFs' CMs from nonmetastatic and postmenopausal patients treated ex vivo with calcitriol decreased the migration of MCF-7 cells.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer-associated fibroblasts (CAFs) play an important role in the tumor microenvironment. Despite the well-known in vitro antitumoral effect of vitamin D
METHODS
METHODS
CAFs were cultured with 1 and 10 nM calcitriol and their phenotype; gene expression, protein expression, and secretion were assessed. Calcitriol-treated CAFs-conditioned media (CM) were used to analyze the effect of CAFs on the migration and protein expression of MCF-7 and MDA-MB-231 cells.
RESULTS
RESULTS
Tumor tissues from VD
CONCLUSION
CONCLUSIONS
The effects of calcitriol on breast CAFs, both at the gene and protein levels, are complex, reflecting the immunosuppressive or procancer properties of CAFs. The anticancer polarization of CAFs following ex vivo calcitriol treatment may result from decreased CCL2, TNC (gene and protein), MMP9, and MMP-2, while the opposite effect may result from increased PDPN, TIMP1 (gene and protein), and SPP1. Despite these multifaceted effects of calcitriol on molecule expression, CAFs' CMs from nonmetastatic and postmenopausal patients treated ex vivo with calcitriol decreased the migration of MCF-7 cells.
Identifiants
pubmed: 38360633
doi: 10.1186/s12885-024-11961-z
pii: 10.1186/s12885-024-11961-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
209Subventions
Organisme : Polish National Science Center
ID : 2017/27/B/NZ5/01167
Organisme : Polish National Science Center
ID : 2017/27/B/NZ5/01167
Organisme : Polish National Science Center
ID : 2017/27/B/NZ5/01167
Organisme : Polish National Science Center
ID : 2017/27/B/NZ5/01167
Organisme : Polish National Science Center
ID : 2017/27/B/NZ5/01167
Organisme : Polish National Science Center
ID : 2017/27/B/NZ5/01167
Organisme : Polish National Science Center
ID : 2017/27/B/NZ5/01167
Organisme : Polish National Science Center
ID : 2017/27/B/NZ5/01167
Organisme : Polish National Science Center
ID : 2017/27/B/NZ5/01167
Informations de copyright
© 2024. The Author(s).
Références
Giorello MB, Borzone FR, Labovsky V, Piccioni FV, Chasseing NA. Cancer-associated fibroblasts in the breast tumor microenvironment. J Mammary Gland Biol Neoplasia. 2021;26(2):135–55.
pubmed: 33398516
doi: 10.1007/s10911-020-09475-y
Vanhevel J, Verlinden L, Doms S, Wildiers H, Verstuyf A. The role of vitamin D in breast cancer risk and progression. Endocr Relat Cancer. 2022;29(2):R33-55.
pubmed: 34935629
doi: 10.1530/ERC-21-0182
Estébanez N, Gómez-Acebo I, Palazuelos C, Llorca J, Dierssen-Sotos T. Vitamin D exposure and risk of breast cancer: a meta-analysis. Sci Rep. 2018;8(1):9039.
pubmed: 29899554
pmcid: 5997996
doi: 10.1038/s41598-018-27297-1
Ganji V, Sukik L, Hoque B, Boutefnouchet L, Shi Z. Association of serum 25-hydroxyvitamin D concentration with breast cancer risk in postmenopausal women in the US. J Pers Med. 2022;12(6):944.
pubmed: 35743729
pmcid: 9225599
doi: 10.3390/jpm12060944
Ordóñez-Mena JM, Schöttker B, Fedirko V, Jenab M, Olsen A, Halkjær J, et al. Pre-diagnostic vitamin D concentrations and cancer risks in older individuals: an analysis of cohorts participating in the CHANCES consortium. Eur J Epidemiol. 2016;31(3):311–23.
pubmed: 25977096
doi: 10.1007/s10654-015-0040-7
Kanstrup C, Teilum D, Rejnmark L, Bigaard JV, Eiken P, Kroman N, et al. 25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival. Breast Cancer Res Treat. 2020;179(3):699–708.
pubmed: 31707511
doi: 10.1007/s10549-019-05486-4
Voutsadakis IA. Vitamin D baseline levels at diagnosis of breast cancer: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2021;14(1):16–26.
pubmed: 33002425
doi: 10.1016/j.hemonc.2020.08.005
Karthikayan A, Sureshkumar S, Kadambari D, Vijayakumar C. Low serum 25-hydroxy vitamin D levels are associated with aggressive breast cancer variants and poor prognostic factors in patients with breast carcinoma. Arch Endocrinol Metab. 2018;62(4):452–9.
pubmed: 30304110
pmcid: 10118730
doi: 10.20945/2359-3997000000062
Peppone LJ, Rickles AS, Janelsins MC, Insalaco MR, Skinner KA. The association between breast cancer prognostic indicators and serum 25-OH vitamin D levels. Ann Surg Oncol. 2012;19(8):2590–9.
pubmed: 22446898
pmcid: 4158737
doi: 10.1245/s10434-012-2297-3
Al-Azhri J, Zhang Y, Bshara W, Zirpoli G, McCann SE, Khoury T, et al. Tumor expression of vitamin D receptor and breast cancer histopathological characteristics and prognosis. Clin Cancer Res. 2017;23(1):97–103.
pubmed: 27407090
doi: 10.1158/1078-0432.CCR-16-0075
Zhalehjoo N, Shakiba Y, Panjehpour M. Gene expression profiles of CYP24A1 and CYP27B1 in malignant and normal breast tissues. Mol Med Rep. 2017;15(1):467–73.
pubmed: 27922682
doi: 10.3892/mmr.2016.5992
Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, et al. Alterations in vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer. 2010;11(10):483.
doi: 10.1186/1471-2407-10-483
Manson JE, Bassuk SS, Buring JE. Principal results of the VITamin D and OmegA-3 TriaL (VITAL) and updated meta-analyses of relevant vitamin D trials. J Steroid Biochem Mol Biol. 2020;198:105522.
pubmed: 31733345
doi: 10.1016/j.jsbmb.2019.105522
Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174–86.
pubmed: 31980749
pmcid: 7046529
doi: 10.1038/s41568-019-0238-1
Dvorak HF. Tumors: wounds that do not heal. N Engl J Med. 1986;315(26):1650–9.
pubmed: 3537791
doi: 10.1056/NEJM198612253152606
Ganguly D, Chandra R, Karalis J, Teke M, Aguilera T, Maddipati R, et al. Cancer-associated fibroblasts: versatile players in the tumor microenvironment. Cancers (Basel). 2020;12(9):2652.
pubmed: 32957515
doi: 10.3390/cancers12092652
Ziani L, Chouaib S, Thiery J. Alteration of the antitumor immune response by cancer-associated fibroblasts. Front Immunol. 2018;9:414.
pubmed: 29545811
pmcid: 5837994
doi: 10.3389/fimmu.2018.00414
Avagliano A, Granato G, Ruocco MR, Romano V, Belviso I, Carfora A, et al. Metabolic reprogramming of cancer associated fibroblasts: the slavery of stromal fibroblasts. Biomed Res Int. 2018;2018:6075403.
pubmed: 29967776
pmcid: 6008683
doi: 10.1155/2018/6075403
Abu El Maaty MA, Grelet E, Keime C, Rerra AI, Gantzer J, Emprou C, et al. Single-cell analyses unravel cell type-specific responses to a vitamin D analog in prostatic precancerous lesions. Sci Adv. 2021;7(31):eabg5982.
pubmed: 34330705
pmcid: 8324049
doi: 10.1126/sciadv.abg5982
Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014;159(1):80–93.
pubmed: 25259922
pmcid: 4177038
doi: 10.1016/j.cell.2014.08.007
Kong F, Li L, Wang G, Deng X, Li Z, Kong X. VDR signaling inhibits cancer-associated-fibroblasts’ release of exosomal miR-10a-5p and limits their supportive effects on pancreatic cancer cells. Gut. 2019;68(5):950–1.
pubmed: 29695492
doi: 10.1136/gutjnl-2018-316627
Mukai Y, Yamada D, Eguchi H, Iwagami Y, Asaoka T, Noda T, et al. Vitamin D supplementation is a promising therapy for pancreatic ductal adenocarcinoma in conjunction with current chemoradiation therapy. Ann Surg Oncol. 2018;25(7):1868–79.
pubmed: 29675761
doi: 10.1245/s10434-018-6431-8
Gorchs L, Ahmed S, Mayer C, Knauf A, Fernández Moro C, Svensson M, et al. The vitamin D analogue calcipotriol promotes an anti-tumorigenic phenotype of human pancreatic CAFs but reduces T cell mediated immunity. Sci Rep. 2020;10(1):17444.
pubmed: 33060625
pmcid: 7562723
doi: 10.1038/s41598-020-74368-3
Zhao ZX, Zhang YQ, Sun H, Chen ZQ, Chang JJ, Wang X, et al. Calcipotriol abrogates cancer-associated fibroblast-derived IL-8-mediated oxaliplatin resistance in gastric cancer cells via blocking PI3K/Akt signaling. Acta Pharmacol Sin. 2023;44(1):178–88.
pubmed: 35676532
doi: 10.1038/s41401-022-00927-1
Ferrer-Mayorga G, Gómez-López G, Barbáchano A, Fernández-Barral A, Peña C, Pisano DG, et al. Vitamin D receptor expression and associated gene signature in tumour stromal fibroblasts predict clinical outcome in colorectal cancer. Gut. 2017;66(8):1449–62.
pubmed: 27053631
doi: 10.1136/gutjnl-2015-310977
Ferrer-Mayorga G, Niell N, Cantero R, González-Sancho JM, Del Peso L, Muñoz A, et al. Vitamin D and Wnt3A have additive and partially overlapping modulatory effects on gene expression and phenotype in human colon fibroblasts. Sci Rep. 2019;9(1):8085.
pubmed: 31147591
pmcid: 6542853
doi: 10.1038/s41598-019-44574-9
Łabędź N, Stachowicz-Suhs M, Psurski M, Anisiewicz A, Banach J, Piotrowska A, et al. Modulation of fibroblast activity via vitamin D3 is dependent on tumor type-studies on mouse mammary gland cancer. Cancers (Basel). 2022;14(19):4585.
pubmed: 36230508
doi: 10.3390/cancers14194585
Campos LT, Brentani H, Roela RA, Katayama MLH, Lima L, Rolim CF, et al. Differences in transcriptional effects of 1α,25 dihydroxyvitamin D3 on fibroblasts associated to breast carcinomas and from paired normal breast tissues. J Steroid Biochem Mol Biol. 2013;133:12–24.
pubmed: 22939885
doi: 10.1016/j.jsbmb.2012.08.002
Perez K. Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Patients With Metastatic Pancreatic Cancer. clinicaltrials.gov; 2024. Report No.: NCT03520790. Available from: https://clinicaltrials.gov/study/NCT03520790 . Cited 2024 Jan 1.
Ha SY, Yeo SY, Xuan YH, Kim SH. The prognostic significance of cancer-associated fibroblasts in esophageal squamous cell carcinoma. PLOS One. 2014;9(6):e99955.
pubmed: 24945657
pmcid: 4063790
doi: 10.1371/journal.pone.0099955
Płudowski P, Karczmarewicz E, Bayer M, Carter G, Chlebna-Sokół D, Czech-Kowalska J, et al. Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe - recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol Pol. 2013;64(4):319–27.
pubmed: 24002961
doi: 10.5603/EP.2013.0012
Anisiewicz A, Kowalski K, Banach J, Łabędź N, Stachowicz-Suhs M, Piotrowska A, et al. Vitamin D metabolite profile in cholecalciferol- or calcitriol-supplemented healthy and mammary gland tumor-bearing mice. Nutrients. 2020;12(11):3416.
pubmed: 33172201
pmcid: 7695033
doi: 10.3390/nu12113416
Kretzschmar M. Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer. Breast Cancer Res. 2000;2(2):107–15.
pubmed: 11250700
pmcid: 139432
doi: 10.1186/bcr42
Bresson L, Faraldo MM, Di-Cicco A, Quintanilla M, Glukhova MA, Deugnier MA. Podoplanin regulates mammary stem cell function and tumorigenesis by potentiating Wnt/β-catenin signaling. Development. 2018;145(4):dev160382.
pubmed: 29361573
doi: 10.1242/dev.160382
Pickup M, Novitskiy S, Moses HL. The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer. 2013;13(11):788–99.
pubmed: 24132110
pmcid: 4025940
doi: 10.1038/nrc3603
Działo E, Czepiel M, Tkacz K, Siedlar M, Kania G, Błyszczuk P. WNT/β-catenin signaling promotes TGF-β-mediated activation of human cardiac fibroblasts by enhancing IL-11 production. Int J Mol Sci. 2021;22(18):10072.
pubmed: 34576234
pmcid: 8468519
doi: 10.3390/ijms221810072
Liu T, Zhou L, Yang K, Iwasawa K, Kadekaro AL, Takebe T, et al. The β-catenin/YAP signaling axis is a key regulator of melanoma-associated fibroblasts. Signal Transduct Target Ther. 2019;4:63.
pubmed: 31885878
pmcid: 6928146
doi: 10.1038/s41392-019-0100-7
Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev. 2016;96(1):365–408.
pubmed: 26681795
doi: 10.1152/physrev.00014.2015
Wei R, Wong JPC, Kwok HF. Osteopontin – a promising biomarker for cancer therapy. J Cancer. 2017;8(12):2173–83.
pubmed: 28819419
pmcid: 5560134
doi: 10.7150/jca.20480
Butti R, Nimma R, Kundu G, Bulbule A, Kumar TVS, Gunasekaran VP, et al. Tumor-derived osteopontin drives the resident fibroblast to myofibroblast differentiation through Twist1 to promote breast cancer progression. Oncogene. 2021;40(11):2002–17.
pubmed: 33603163
doi: 10.1038/s41388-021-01663-2
Weber CE, Kothari AN, Wai PY, Li NY, Driver J, Zapf MAC, et al. Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer. Oncogene. 2015;34(37):4821–33.
pubmed: 25531323
doi: 10.1038/onc.2014.410
Williams JD, Aggarwal A, Swami S, Krishnan AV, Ji L, Albertelli MA, et al. Tumor autonomous effects of vitamin D deficiency promote breast cancer metastasis. Endocrinology. 2016;157(4):1341–7.
pubmed: 26934299
pmcid: 4816742
doi: 10.1210/en.2015-2036
Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res. 1999;5(6):1339–45.
pubmed: 10389917
Swami S, Krishnan AV, Williams J, Aggarwal A, Albertelli MA, Horst RL, et al. Vitamin D mitigates the adverse effects of obesity on breast cancer in mice. Endocr Relat Cancer. 2016;23(4):251–64.
pubmed: 26817629
pmcid: 4889430
doi: 10.1530/ERC-15-0557
Raskov H, Orhan A, Gaggar S, Gögenur I. Cancer-associated fibroblasts and tumor-associated macrophages in cancer and cancer immunotherapy. Front Oncol. 2021;11:668731.
pubmed: 34094963
pmcid: 8172975
doi: 10.3389/fonc.2021.668731
Rotondo R, Barisione G, Mastracci L, Grossi F, Orengo AM, Costa R, et al. IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. Int J Cancer. 2009;125(4):887–93.
pubmed: 19431148
doi: 10.1002/ijc.24448
Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol. 2002;168(2):689–95.
pubmed: 11777962
doi: 10.4049/jimmunol.168.2.689
Talts JF, Wirl G, Dictor M, Muller WJ, Fässler R. Tenascin-C modulates tumor stroma and monocyte/macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer. J Cell Sci. 1999;112(Pt 12):1855–64.
pubmed: 10341205
doi: 10.1242/jcs.112.12.1855
Suzuki J, Aokage K, Neri S, Sakai T, Hashimoto H, Su Y, et al. Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. Lung Cancer. 2021;153:1–10.
pubmed: 33429158
doi: 10.1016/j.lungcan.2020.12.020
Jachetti E, Caputo S, Mazzoleni S, Brambillasca CS, Parigi SM, Grioni M, et al. Tenascin-C Protects Cancer Stem–like Cells from Immune Surveillance by Arresting T-cell Activation. Can Res. 2015;75(10):2095–108.
doi: 10.1158/0008-5472.CAN-14-2346
Song X, Si Q, Qi R, Liu W, Li M, Guo M, et al. Indoleamine 2,3-dioxygenase 1: a promising therapeutic target in malignant tumor. Front Immunol. 2021;12:800630.
pubmed: 35003126
pmcid: 8733291
doi: 10.3389/fimmu.2021.800630
Heng B, Lim CK, Lovejoy DB, Bessede A, Gluch L, Guillemin GJ. Understanding the role of the kynurenine pathway in human breast cancer immunobiology. Oncotarget. 2016;7(6):6506–20.
pubmed: 26646699
doi: 10.18632/oncotarget.6467
Bilir C, Sarisozen C. Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller? J Oncological Sci. 2017;3(2):52–6.
doi: 10.1016/j.jons.2017.04.001
Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med. 2001;7(10):1118–22.
pubmed: 11590434
doi: 10.1038/nm1001-1118
Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 2001;61(1):237–42.
pubmed: 11196168
Kim SH, Baek MS, Yoon DS, Park JS, Yoon BW, Oh BS, et al. Vitamin D inhibits expression and activity of matrix metalloproteinase in human lung fibroblasts (HFL-1) cells. Tuberc Respir Dis (Seoul). 2014;77(2):73–80.
pubmed: 25237378
doi: 10.4046/trd.2014.77.2.73
Anisiewicz A, Pawlik A, Filip-Psurska B, Wietrzyk J. Differential impact of calcitriol and its analogs on tumor stroma in young and aged ovariectomized mice bearing 4T1 mammary gland cancer. Int J Mol Sci. 2020;21(17):6359.
pubmed: 32887237
pmcid: 7503326
doi: 10.3390/ijms21176359
Cao Y, Du Y, Liu F, Feng Y, Cheng S, Guan S, et al. Vitamin D aggravates breast cancer by inducing immunosuppression in the tumor bearing mouse. Immunotherapy. 2018;10(7):555–66.
pubmed: 29852828
doi: 10.2217/imt-2017-0131
Pawlik A, Anisiewicz A, Filip-Psurska B, Nowak M, Turlej E, Trynda J, et al. Calcitriol and its analogs establish the immunosuppressive microenvironment that drives metastasis in 4T1 mouse mammary gland cancer. Int J Mol Sci. 2018;19(7):2116.
pubmed: 30037009
pmcid: 6073894
doi: 10.3390/ijms19072116
Tie Y, Tang F, Wei YQ, Wei XW. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022;15(1):61.
pubmed: 35585567
pmcid: 9118588
doi: 10.1186/s13045-022-01282-8
Lambert E, Dassé E, Haye B, Petitfrère E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol. 2004;49(3):187–98.
pubmed: 15036259
doi: 10.1016/j.critrevonc.2003.09.008
Cheng G, Fan X, Hao M, Wang J, Zhou X, Sun X. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer. Mol Cancer. 2016;15(1):30.
pubmed: 27130446
pmcid: 4851824
doi: 10.1186/s12943-016-0515-5
Song G, Xu S, Zhang H, Wang Y, Xiao C, Jiang T, et al. TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway. J Exp Clin Cancer Res. 2016;35(1):148.
pubmed: 27644693
pmcid: 5028967
doi: 10.1186/s13046-016-0427-7
Shou Y, Liu Y, Xu J, Liu J, Xu T, Tong J, et al. TIMP1 indicates poor prognosis of renal cell carcinoma and accelerates tumorigenesis via EMT signaling pathway. Front Genet. 2022;13:648134.
pubmed: 35281807
pmcid: 8914045
doi: 10.3389/fgene.2022.648134
Ando T, Charindra D, Shrestha M, Umehara H, Ogawa I, Miyauchi M, et al. Tissue inhibitor of metalloproteinase-1 promotes cell proliferation through YAP/TAZ activation in cancer. Oncogene. 2018;37(2):263–70.
pubmed: 28925394
doi: 10.1038/onc.2017.321
Wang T, Yamashita K, Iwata K, Hayakawa T. Both tissue inhibitors of metalloproteinases-1 (TIMP-1) and TIMP-2 activate Ras but through different pathways. Biochem Biophys Res Commun. 2002;296(1):201–5.
pubmed: 12147251
doi: 10.1016/S0006-291X(02)00741-6
Jung KK, Liu XW, Chirco R, Fridman R, Kim HRC. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J. 2006;25(17):3934–42.
pubmed: 16917503
pmcid: 1560352
doi: 10.1038/sj.emboj.7601281
Lambert E, Boudot C, Kadri Z, Soula-Rothhut M, Sowa ML, Mayeux P, et al. Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. Biochem J. 2003;372(Pt 3):767–74.
pubmed: 12639219
pmcid: 1223442
doi: 10.1042/bj20030187
Petitfrère E, Kadri Z, Boudot C, Sowa ML, Mayeux P, Haye B, et al. Involvement of the p38 mitogen-activated protein kinase pathway in tissue inhibitor of metalloproteinases-1-induced erythroid differentiation. FEBS Lett. 2000;485(2–3):117–21.
pubmed: 11094152
doi: 10.1016/S0014-5793(00)02210-9
Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res. 1999;59(24):6267–75.
pubmed: 10626822
Low-Marchelli JM, Ardi VC, Vizcarra EA, van Rooijen N, Quigley JP, Yang J. Twist1 induces CCL2 and recruits macrophages to promote angiogenesis. Cancer Res. 2013;73(2):662–71.
pubmed: 23329645
pmcid: 3566985
doi: 10.1158/0008-5472.CAN-12-0653
Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One. 2009;4(8):e6562.
pubmed: 19668347
pmcid: 2721818
doi: 10.1371/journal.pone.0006562
Fang WB, Jokar I, Zou A, Lambert D, Dendukuri P, Cheng N. CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms. J Biol Chem. 2012;287(43):36593–608.
pubmed: 22927430
pmcid: 3476325
doi: 10.1074/jbc.M112.365999
O’Connell JT, Sugimoto H, Cooke VG, MacDonald BA, Mehta AI, LeBleu VS, et al. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci U S A. 2011;108(38):16002–7.
pubmed: 21911392
pmcid: 3179047
doi: 10.1073/pnas.1109493108
González-Sancho JM, Alvarez-Dolado M, Muñoz A. 1,25-Dihydroxyvitamin D3 inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett. 1998;426(2):225–8.
pubmed: 9599013
doi: 10.1016/S0014-5793(98)00348-2
Oskarsson T, Acharyya S, Zhang XHF, Vanharanta S, Tavazoie SF, Morris PG, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med. 2011;17(7):867–74.
pubmed: 21706029
pmcid: 4020577
doi: 10.1038/nm.2379
Cai HP, Wang J, Xi SY, Ni XR, Chen YS, Yu YJ, et al. Tenascin-cmediated vasculogenic mimicry formation via regulation of MMP2/MMP9 in glioma. Cell Death Dis. 2019;10(12):879.
pubmed: 31754182
pmcid: 6872754
doi: 10.1038/s41419-019-2102-3
Li J, Luco AL, Camirand A, St-Arnaud R, Kremer R. Vitamin D regulates CXCL12/CXCR4 and epithelial-to-mesenchymal transition in a model of breast cancer metastasis to lung. Endocrinology. 2021;162(7):bqab049.
pubmed: 33693593
pmcid: 8183495
doi: 10.1210/endocr/bqab049
Neri S, Ishii G, Hashimoto H, Kuwata T, Nagai K, Date H, et al. Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma. Int J Cancer. 2015;137(4):784–96.
pubmed: 25648219
doi: 10.1002/ijc.29464
Shindo K, Aishima S, Ohuchida K, Fujiwara K, Fujino M, Mizuuchi Y, et al. Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. Mol Cancer. 2013;12(1):168.
pubmed: 24354864
pmcid: 3916072
doi: 10.1186/1476-4598-12-168
Niemiec J, Adamczyk A, Harazin-Lechowska A, Ambicka A, Grela-Wojewoda A, Majchrzyk K, et al. Podoplanin-positive cancer-associated stromal fibroblasts in primary tumor and synchronous lymph node metastases of HER2-overexpressing breast carcinomas. Anticancer Res. 2018;38(4):1957–65.
pubmed: 29599311
Suchanski J, Tejchman A, Zacharski M, Piotrowska A, Grzegrzolka J, Chodaczek G, et al. Podoplanin increases the migration of human fibroblasts and affects the endothelial cell network formation: A possible role for cancer-associated fibroblasts in breast cancer progression. PLoS One. 2017;12(9):e0184970.
pubmed: 28938000
pmcid: 5609749
doi: 10.1371/journal.pone.0184970
Wu HT, Zhong HT, Li GW, Shen JX, Ye QQ, Zhang ML, et al. Oncogenic functions of the EMT-related transcription factor ZEB1 in breast cancer. J Transl Med. 2020;18(1):51.
pubmed: 32014049
pmcid: 6998212
doi: 10.1186/s12967-020-02240-z
Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia. 2001;6(4):419–29.
pubmed: 12013531
doi: 10.1023/A:1014734930781
Khongsti K, Das B. Osteopontin and breast cancer metastasis: Possible role of genistein on the regulation of osteopontin. Phytomedicine Plus. 2021;1(4):100138.
doi: 10.1016/j.phyplu.2021.100138
Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, et al. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8(10):1118.
pubmed: 31547193
pmcid: 6830116
doi: 10.3390/cells8101118
Matsumura Y, Ito Y, Mezawa Y, Sulidan K, Daigo Y, Hiraga T, et al. Stromal fibroblasts induce metastatic tumor cell clusters via epithelial-mesenchymal plasticity. Life Sci Alliance. 2019;2(4):e201900425.
pubmed: 31331982
pmcid: 6653778
doi: 10.26508/lsa.201900425